GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » Shares Buyback Ratio %

Renovaro (Renovaro) Shares Buyback Ratio % : -20.68 (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Renovaro Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Renovaro's current shares buyback ratio was -20.68%.

Renovaro Shares Buyback Ratio % Historical Data

The historical data trend for Renovaro's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro Shares Buyback Ratio % Chart

Renovaro Annual Data
Trend Mar13 Dec14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.19 -2.70 -12.31 -1.51 -20.17

Renovaro Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.36 -4.09 -9.86 -3.14 -2.32

Renovaro Shares Buyback Ratio % Calculation

Renovaro's Shares Buyback Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2022 ) - Shares Outstanding (EOP) (A: Jun. 2023 )) / Shares Outstanding (EOP) (A: Jun. 2022 )
=(53.0071 - 63.6981) / 53.0071
=-20.17%

Renovaro's Shares Buyback Ratio for the quarter that ended in Dec. 2023 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Sep. 2023 ) - Shares Outstanding (EOP) (A: Dec. 2023 )) / Shares Outstanding (EOP) (A: Sep. 2023 )
=(65.6981 - 67.2241) / 65.6981
=-2.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renovaro Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Renovaro's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovaro (Renovaro) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » Shares Buyback Ratio %
Comparable Companies
AEON SCPH INZY ENTA MCRB IVVD GRTS DNTH CBUS PSTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
2Q5:Germany
Address
2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Website
https://www.enochianbio.com
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.
Executives
Leni Boeren director 2080 CENTURY PARK EAST, #906, LOS ANGELES CA 90067
Ruud Hendriks director CHATEAU D'AZUR, BLVD D'LTALIE 44, MONACO O9 C11298000
Ole Abildgaard 10 percent owner VEDBAEK STRANDVEJ 506, VEDBAEK G7 2950
Francois Binette officer: Executive Vice President 2022 N. ALVARADO STREET, LOS ANGELES CA 90039
Serhat Gumrukcu 10 percent owner 2080 CENTURY CITY EAST, SUITE 906, LOS ANGELES CA 90067
Rene Sindlev director, 10 percent owner FRUEBJERGVEJ 3 BOX 62, COPENHAGEN G7 2100
Carl Forest Sandler other: Former director see note below 330 EAST 33RD STREET, APARTMENT 3A, NEW YORK FL 10016
Jayne Mcnicol director 606 NORTHERN AVENUE, MILL VALLEY CA 94941
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Carol L Brosgart director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Henrik Gronfeldt-sorensen director STUMPEDYSSEVEJ 17, HORSHOLM G7 2970
Luisa Puche officer: Chief Financial Officer 318 NE 104TH STREET, MIAMI FL 33138
Luc Debruyne director NOORDENWINDHELLING 2 02/05, OOSTDUINKERKE C9 8670
Anderson Wittekind William 10 percent owner 8581 SANTA MONICA BLVD, LOS ANGELES CA 90069
Leire, Eric Jean Marie director, officer: CEO; President C/O DANDRIT BIOTECH USA, INC., P.O. BOX 189, RANDOLPH VT 05060